Search results for "thiophenes"

showing 10 items of 80 documents

The influence of erdosteine administration on lead-induced oxidative stress in rat muscle.

2019

Lead-exposure is known to disrupt the redox balance of tissues leading to oxidative stress. Due to the fact that a mucolytic drug, erdosteine, exerts also antioxidant properties, we decided to perform a pilot study on rats to evaluate its therapeutic potency in lead poisoning. Male Wistar rats were divided randomly into the following seven groups having 10 animals in each. Group I served as the control group. During 8-week period, rats in groups II-IV, except standard alimentation, received: erdosteine in a dose 350 mg/kg (collateral control group), 1200 ppm of lead acetate in drinking water and placebo, as well as the same doses of lead and erdosteine, respectively. Rats in group V-VII rec…

MaleAntioxidantErdosteinemuscleHealth Toxicology and Mutagenesismedicine.medical_treatmentErdosteinePilot ProjectsThiophenes010501 environmental sciencesPharmacologyToxicologymedicine.disease_cause01 natural sciencesLead poisoningAntioxidants03 medical and health sciences0302 clinical medicineMalondialdehydemedicineAnimalsRats WistarLead (electronics)0105 earth and related environmental sciencesPharmacologyChemical Health and SafetyChemistrySuperoxide DismutaseMusclesPublic Health Environmental and Occupational Healthlead poisoningGeneral Medicinemedicine.diseaseCatalaseRatsOxidative StressLeadThioglycolates030217 neurology & neurosurgeryOxidative stressmedicine.drugDrug and chemical toxicology
researchProduct

Measurement of Duloxetine in Blood Using High-performance Liquid Chromatography with Spectrophotometric Detection and Column Switching

2007

A method using high-performance liquid chromatography (HPLC) with column switching and ultraviolet (UV) spectroscopy was developed for the determination of duloxetine in human plasma. After centrifugation and addition of venlafaxine as internal standard, plasma samples were injected into the HPLC system and precleaned on a column (10 x 4.0 mm) filled with cyanopropyl (CN)-modified silica of 20 microm particle size, with use of 8% (vol/vol) acetonitrile in deionized water as eluent. Duloxetine was eluted and separated on a LiChrospher 100 CN (5-microm particle size; column size, 250 x 4.6 mm I.D.) using acetonitrile-water-potassium dihydrogenphosphate trihydrate buffer (pH, 6.4; 50:50 vol/vo…

MaleChlorprothixeneThiophenesDuloxetine HydrochlorideDuloxetine HydrochlorideHigh-performance liquid chromatographyColumn chromatographyPharmacokineticsmedicineHumansDrug InteractionsPharmacology (medical)Chromatography High Pressure LiquidPharmacologyDetection limitChromatographyMolecular Structuremedicine.diagnostic_testElutionChemistrySpectrophotometryTherapeutic drug monitoringFemaleDrug MonitoringSelective Serotonin Reuptake Inhibitorsmedicine.drugTherapeutic Drug Monitoring
researchProduct

Effectiveness of Duloxetine Compared With Pregabalin and Gabapentin in Diabetic Peripheral Neuropathic Pain

2013

This study aimed to compare the effectiveness of duloxetine (DLX) and the anticonvulsants pregabalin (PGB) and gabapentin (GBP) for the treatment of diabetic peripheral neuropathic pain (DPNP) in routine clinical care.Data from a 6-month, noninterventional study involving 2575 patients in whom treatment of DPNP was initiated with or changed to DLX, PGB, or GBP (n=1523) were analyzed post hoc; patients treated with other medications or combinations were excluded from this analysis. Propensity scoring was used to compare patient groups, assessing Brief Pain Inventory (BPI), Clinical and Patient Global Impression (CGI/PGI), the Hospital Anxiety and Depression Scale (HADS), the Sheehan Disabili…

MaleCyclohexanecarboxylic AcidsGabapentinPregabalinPregabalinThiophenesDuloxetine HydrochlorideDuloxetine Hydrochloridechemistry.chemical_compoundDiabetic NeuropathiesGermanyHumansMedicineDuloxetineProspective StudiesAminesProspective cohort studygamma-Aminobutyric AcidAgedPain MeasurementAnalgesicsChi-Square Distributionbusiness.industryMiddle AgedHealth SurveysPeripheral neuropathic painTreatment OutcomeAnesthesiology and Pain MedicineMulticenter studychemistryAnesthesiaFemaleObservational studyNeurology (clinical)Gabapentinbusinessmedicine.drugThe Clinical Journal of Pain
researchProduct

The Heidelberg retina tomograph ancillary study to the European glaucoma prevention study: study design and baseline factors.

2013

Purpose: To describe the study design and baseline factors of the Heidelberg Retina Tomograph ancillary study within the EGPS. Furthermore, to examine the relationship between HRT optic disc topographic measurements and baseline demographic and ocular factors. Methods: Four hundred and eighty-nine ocular hypertensive participants were included. Each participant completed HRT imaging at least annually. The associations between HRT measurements and IOP, central corneal thickness (CCT), baseline photographic estimates of vertical CDR ratio (CDR), asymmetry between the two eyes in CDR ratio and baseline visual field indices were assessed using regression analysis. Results: Associations between …

MaleIntraocular pressureVisual acuitygenetic structuresOptic diskVisual AcuityOcular hypertensionGlaucomaOptic Nerve DiseasesMedicineHRT parameterCarbonic Anhydrase Inhibitorspattern standard deviationTomographySulfonamidesmedicine.diagnostic_testGeneral MedicineMiddle Agedmedicine.anatomical_structureResearch DesignOptic nerveFemalemedicine.symptomHumanOptic discmedicine.medical_specialtyCarbonic Anhydrase Inhibitorscanning laser ophthalmoscopyOptic DiskVisual FieldThiophenesSulfonamideOphthalmoscopyTonometry OcularOptic Nerve DiseaseDouble-Blind MethodThiopheneOphthalmologymental disordersHumansIntraocular Pressurebusiness.industryGlaucomamedicine.diseaseeye diseasesOphthalmoscopyOphthalmologyOcular Hypertensionsense organsVisual Fieldsbusinesscentral corneal thickneActa ophthalmologica
researchProduct

Efficacy and safety of preoperative IOP reduction using a preservative-free fixed combination of dorzolamide/timolol eye drops versus oral acetazolam…

2017

Introduction To demonstrate that preoperative treatment for 28 days with topical dorzolamide/timolol is non-inferior (Δ = 4 mm Hg) to oral acetazolamide and topical dexamethasone (standard therapy) in terms of intraocular pressure (IOP) reduction 3 and 6 months after trabeculectomy in glaucoma patients. Materials and methods Sixty-two eyes undergoing trabeculectomy with mitomycin C were included in this monocentric prospective randomized controlled study. IOP change between baseline and 3 months post-op was defined as the primary efficacy variable. Secondary efficacy variables included the number of 5-fluorouracil (5-FU) injections, needlings, suture lyses, preoperative IOP change, hyperten…

MaleIntraocular pressuregenetic structuresEye DiseasesPhysiologymedicine.medical_treatmentTimololGlaucomalcsh:Medicine030204 cardiovascular system & hematologyDexamethasone0302 clinical medicineGlaucoma surgeryMedicine and Health SciencesMedicineTrabeculectomyProspective Studieslcsh:ScienceSulfonamidesMultidisciplinaryPharmaceuticsDorzolamide/TimololOphthalmic ProceduresMiddle AgedDrug CombinationsTreatment OutcomeResearch DesignAnesthesiaTimololFemaleFluorouracilAnatomyAcetazolamidemedicine.drugResearch Articlemedicine.medical_specialtyLysis (Medicine)Clinical Research DesignSurgical and Invasive Medical ProceduresTrabeculectomyThiophenesResearch and Analysis Methods03 medical and health sciencesMusculoskeletal System ProceduresDorzolamideDrug TherapyOcular SystemOphthalmologyTissue RepairPreoperative CareHumansAntihypertensive AgentsIntraocular PressureAgedbusiness.industrylcsh:RBiology and Life SciencesGlaucomamedicine.diseaseeye diseasesAcetazolamideOphthalmology030221 ophthalmology & optometryEyeslcsh:QOcular Hypertensionsense organsAdverse EventsOphthalmic SolutionsbusinessPhysiological ProcessesHeadPLoS ONE
researchProduct

Efficacy and tolerability of preservative-free eye drops containing a fixed combination of dorzolamide and timolol in glaucoma patients.

2010

To evaluate the efficacy and tolerability of preservative-free eye drops (dorzolamide/timolol) in routine management of preservative-sensitive glaucoma patients.Data from 2,298 glaucoma patients requiring intraocular pressure (IOP) reduction and suffering from intolerance to benzalkonium chloride or active agents of previously used eye drops were valid for baseline and safety analysis in this prospective, open, noncomparative, multicenter, noninterventional study. Patients were treated with preservative-free dorzolamide/timolol eye drops for 12 weeks. Main efficacy endpoint was IOP reduction after 12 weeks of treatment. Two thousand forty-nine patients were considered for efficacy analysis.…

MaleIntraocular pressuregenetic structuresEye diseasemedicine.medical_treatmentAdministration TopicalGlaucomaTimololHyperemiaThiophenesDorzolamideMedicineHumansPharmacology (medical)Prospective StudiesProspective cohort studyAntihypertensive AgentsIntraocular PressureAgedPharmacologySulfonamidesbusiness.industryPreservatives PharmaceuticalEye dropmedicine.diseaseeye diseasesOphthalmologyDrug CombinationsTreatment OutcomeTolerabilityAnesthesiaTimololFemalesense organsOphthalmic SolutionsbusinessBenzalkonium CompoundsGlaucoma Open-Anglemedicine.drugJournal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
researchProduct

Rivaroxaban for thromboprophylaxis in acutely ill medical patients.

2013

International audience; BACKGROUND: The clinically appropriate duration of thromboprophylaxis in hospitalized patients with acute medical illnesses is unknown. In this multicenter, randomized, double-blind trial, we evaluated the efficacy and safety of oral rivaroxaban administered for an extended period, as compared with subcutaneous enoxaparin administered for a standard period, followed by placebo. METHODS: We randomly assigned patients 40 years of age or older who were hospitalized for an acute medical illness to receive subcutaneous enoxaparin, 40 mg once daily, for 10±4 days and oral placebo for 35±4 days or to receive subcutaneous placebo for 10±4 days and oral rivaroxaban, 10 mg onc…

MaleMESH: Factor Xa[SDV]Life Sciences [q-bio]Administration Oral030204 cardiovascular system & hematologylaw.inventionMESH: Venous Thromboembolismchemistry.chemical_compound0302 clinical medicineRivaroxabanRandomized controlled triallawMedicineMESH: Double-Blind Method030212 general & internal medicineMESH: AgedMESH: Middle AgedVenous ThromboembolismGeneral MedicineMiddle AgedMESH: Thiophenes3. Good healthAnesthesiaAcute DiseaseMESH: Administration OralMESH: Acute DiseaseFemaleMESH: Hemorrhagemedicine.drugAdultRandomizationMESH: EnoxaparinInjections SubcutaneousMorpholinesMESH: MorpholinesHemorrhageThiophenesMESH: AnticoagulantsMESH: Drug Administration SchedulePlaceboDrug Administration Schedule03 medical and health sciencesDouble-Blind MethodRivaroxaban venous thromboembolismHumansEnoxaparinAgedRivaroxabanMESH: Humansbusiness.industryMESH: Injections SubcutaneousAnticoagulantsMESH: AdultConfidence intervalMESH: MalechemistryBetrixabanRelative riskbusinessVenous thromboembolismMESH: FemaleFactor Xa Inhibitors
researchProduct

Raltitrexed plus levofolinic acid and bolus/continuous infusion 5-fluorouracil on a biweekly schedule for elderly patients with advanced colorectal c…

2006

BACKGROUND: The aim of the study was to evaluate the safety and efficacy of the raltitrexed/5-fluorouracil/levofolinic acid combination regimen as first-line chemotherapy for elderly patients with advanced/metastatic colorectal cancer. PATIENTS AND METHODS: Previously untreated patients with metastatic colorectal cancer received raltitrexed 2 mg/m(2) i.v. plus levofolinic acid and 5-fluorouracil according to the De Gramont' schedule given every 2 weeks as first-line chemotherapy. Patients were re-evaluated after six cycles and chemotherapy was continued up to tolerance or disease progression. RESULTS: Seventy patients aged >/=65 years were accrued from 11 centers between September 2001 and …

MaleOncologymedicine.medical_specialtyColorectal cancerfolinic acidmedicine.medical_treatmentLeucovorincolorectal cancerThiophenesAdenocarcinomaNeutropeniaGastroenterologyDrug Administration ScheduleFolinic acidBolus (medicine)Internal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumans5-fluorouracilNeoplasm MetastasisAgedAged 80 and overChemotherapybusiness.industryraltitrexedHematologymedicine.diseaseRegimenOncologyFluorouracilmetastaseQuinazolinesFemaleFluorouracilNeoplasm Recurrence LocalColorectal NeoplasmsbusinessRaltitrexedmedicine.drugAnnals of Oncology
researchProduct

In vitro anti-inflammatory effects of AZD8999, a novel bifunctional muscarinic acetylcholine receptor antagonist /β2-adrenoceptor agonist (MABA) comp…

2019

Recent evidence indicates that AZD8999 (LAS190792), a novel muscarinic acetylcholine receptor antagonist and β2-adrenoceptor agonist (MABA) in development for chronic respiratory diseases, induces potent and sustained relaxant effects in human bronchi by adressing both muscarinic acetylcholine receptors and β2-adrenoceptor. However, the anti-inflammatory effects of the AZD8999 monotherapy or in combination with corticosteroids are unknown. This study investigates the anti-inflammatory effects of AZD8999 in monotherapy and combined with fluticasone propionate in neutrophils from healthy and chronic obstructive pulmonary disease (COPD) patients. Peripheral blood neutrophils from healthy and C…

MalePulmonologyNeutrophilsPhysiologyAnti-Inflammatory AgentsPharmacologyPathology and Laboratory MedicineBiochemistryPulmonary Disease Chronic ObstructiveWhite Blood CellsGlucocorticoid receptorAnimal CellsMuscarinic acetylcholine receptorMedicine and Health SciencesPost-Translational ModificationPhosphorylationReceptorImmune ResponseMultidisciplinaryPharmaceuticsQRDrug SynergismMiddle AgedReceptors MuscarinicHealthy VolunteersBody FluidsChemistryBloodPhysical SciencesQuinolinesMedicineDrug Therapy CombinationFemalemedicine.symptomCellular TypesAnatomymedicine.drugResearch ArticleSignal TransductionAgonistTransmembrane Receptorsmedicine.drug_classp38 mitogen-activated protein kinasesChronic Obstructive Pulmonary DiseaseImmune CellsScienceImmunologyInflammationMuscarinic AntagonistsThiophenesFluticasone propionateSigns and SymptomsDrug TherapyCyclohexanesDiagnostic MedicinemedicineHumansAdrenergic beta-2 Receptor AgonistsAgedInflammationBlood CellsDose-Response Relationship Drugbusiness.industryAntagonistChemical CompoundsBiology and Life SciencesProteinsCell BiologyAcetylcholine ReceptorsFluticasoneMuscarinic Acetylcholine ReceptorsReceptors Adrenergic beta-2PropionatesbusinessReceptor Antagonist TherapyPLoS ONE
researchProduct

The effects of transdermal rotigotine on non-motor symptoms of Parkinson's disease: a multicentre, observational, retrospective, post-marketing study

2017

This study evaluated the effect of ≥6 months of transdermal rotigotine on non-motor and motor symptoms of patients with advanced Parkinson's disease.The study was conducted in Spain between September 2011 and December 2012 (ClinicalTrials.gov: NCT01504529). The primary efficacy variable was the change from baseline in non-motor symptoms, as assessed by changes in Parkinson's Disease Non-Motor Symptoms Questionnaire total scores at 6 months. Secondary endpoints included the assessment of motor symptoms by Unified Parkinson's Disease Rating Scale III scores.Data from 378 patients (mean age: 70.2 years; 56.9% male) with Parkinson's disease receiving rotigotine from were collected. Mean disease…

MaleSleep Wake Disordersmedicine.medical_specialtyParkinson's diseaseTetrahydronaphthalenesThiophenesDiseaseAdministration CutaneousMotor symptoms03 medical and health sciences0302 clinical medicineSurveys and QuestionnairesProduct Surveillance PostmarketingmedicineHumans030212 general & internal medicineAgedRetrospective StudiesTransdermalAged 80 and overbusiness.industryGeneral NeuroscienceParkinson DiseaseRotigotineGeneral MedicineUrination Disordersmedicine.diseaseClinical PracticeTreatment OutcomeSpainDopamine AgonistsPhysical therapyNon motorFemaleObservational studyCognition Disordersbusiness030217 neurology & neurosurgerymedicine.drugInternational Journal of Neuroscience
researchProduct